HF Combo Therapy Improves Sexual Activity Outcomes

Sacubitril/valsartan combination therapy improves health-related quality of life in patients with heart failure (HF) more significantly than enalapril, according to a new analysis. The most significant improvements were reported in sexual health.

To evaluate sacubitril/valsartan therapy, the researchers conducted a secondary analysis of data from 8399 participants in the PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial.

IF YOU LIKE THIS, READ MORE...

High Protein Intake May Not Prevent Heart Failure

Heart Failure Devices: Answers from the Heart Rhythm Scientific Sessions

Participants were New York Heart Association class II to IV; had a left ventricular ejection fraction of 40% or less; and were being treated in 1043 centers in 38 countries.

At baseline, participants were randomly assigned to either sacubitril/valsartan, 200 mg twice daily, or enalapril, 10 mg twice daily.

Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire at baseline and at 4-month, 8-month, and annual follow-up visits. Questionnaire responses at baseline showed the greatest limitations in jogging and sexual relationships.

After receiving sacubitril/valsartan, however, patients reported better scores in physical and social activities at 8 months and 36 months, compared with those taking enalapril.

Moreover, the researchers say the largest improvements were reported in household chores and sexual relationships, results that persisted through 36 months.

“In addition to improving morbidity and mortality, sacubitril/valsartan may significantly improve limitations in physical and social activities that are common in patients with heart failure, including sexual activities,” the researchers conclude.

—Amanda Balbi

Reference:

Chandra A, Lewis EF, Claggett BL, et al. Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure. JAMA Cardiol. 2018;3(6):498-505. doi:10.1001/jamacardio.2018.0398.

Listen to our podcast with Dr Mikhail Kosiborod and Dr Seth Baum about clinical trial data regarding heart failure: